Holen Sie sich die Stockscreener-App
112.23
1.73%
1.91
Handel nachbörslich:
112.50
0.27
+0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$110.32
Offen:
$111.15
24-Stunden-Volumen:
1.21M
Relative Volume:
0.59
Marktkapitalisierung:
$23.94B
Einnahmen:
$7.41B
Nettoeinkommen (Verlust:
$2.14B
KGV:
12.03
EPS:
9.33
Netto-Cashflow:
$2.70B
1W Leistung:
+0.73%
1M Leistung:
-4.36%
6M Leistung:
+18.94%
1J Leistung:
+5.58%
1-Tages-Spanne:
$110.83
$113.35
1-Wochen-Bereich:
$109.40
$113.35
52-Wochen-Spanne:
$85.22
$122.00
T Rowe Price Group Inc Stock (TROW) Company Profile
Firmenname
T Rowe Price Group Inc
Sektor
Branche
Telefon
(410) 345-2000
Adresse
HARBOR POINT, BALTIMORE, MD
Compare TROW vs BLK, BX, BN, BAM, APO
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TROW
T Rowe Price Group Inc
|
112.23 | 23.53B | 7.41B | 2.14B | 2.70B | 9.33 |
BLK
Blackrock Inc
|
1,158.92 | 178.77B | 27.61B | 7.13B | 3.76B | 40.76 |
BX
Blackstone Inc
|
145.09 | 105.53B | 16.59B | 6.83B | 869.79M | 4.4576 |
BN
Brookfield Corp
|
42.15 | 94.05B | 77.61B | 4.06B | -8.36B | 0.497 |
BAM
Brookfield Asset Management Ltd
|
52.65 | 82.21B | 5.07B | 2.48B | 2.37B | 1.5532 |
APO
Apollo Global Management Inc
|
133.63 | 79.04B | 31.69B | 2.94B | 8.43B | 1.5206 |
T Rowe Price Group Inc Stock (TROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-03 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-09-12 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-08-27 | Eingeleitet | Barclays | Underweight |
| 2024-04-11 | Hochstufung | Keefe Bruyette | Underperform → Mkt Perform |
| 2024-04-08 | Hochstufung | TD Cowen | Sell → Hold |
| 2024-01-08 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-01-04 | Eingeleitet | TD Cowen | Underperform |
| 2023-10-31 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-05-19 | Eingeleitet | Citigroup | Sell |
| 2022-12-15 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Eingeleitet | Credit Suisse | Underperform |
| 2022-07-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-29 | Herabstufung | Keefe Bruyette | Mkt Perform → Underperform |
| 2022-06-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-04-11 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-12 | Bestätigt | Citigroup | Sell |
| 2022-01-04 | Herabstufung | Goldman | Neutral → Sell |
| 2021-12-17 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-16 | Fortgesetzt | BofA Securities | Underperform |
| 2021-10-22 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-04-14 | Herabstufung | Citigroup | Neutral → Sell |
| 2021-03-30 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-05 | Hochstufung | Goldman | Sell → Neutral |
| 2020-11-19 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-24 | Herabstufung | Goldman | Neutral → Sell |
| 2020-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2019-10-08 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-03-08 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-31 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-01-04 | Herabstufung | Goldman | Buy → Neutral |
| 2018-12-06 | Bestätigt | BofA/Merrill | Buy |
| 2018-10-26 | Bestätigt | Barclays | Underweight |
| 2018-09-07 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2018-05-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-01-09 | Hochstufung | UBS | Sell → Neutral |
| 2018-01-08 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-10-27 | Bestätigt | Barclays | Underweight |
| 2017-10-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2017-09-28 | Hochstufung | Goldman | Neutral → Buy |
| 2017-09-08 | Eingeleitet | Barclays | Underweight |
| 2017-05-24 | Herabstufung | UBS | Buy → Sell |
| 2017-04-26 | Herabstufung | Argus | Buy → Hold |
| 2017-03-17 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
Alle ansehen
T Rowe Price Group Inc Aktie (TROW) Neueste Nachrichten
T. Rowe Price Group Stock: Analyst Estimates & Ratings - Yahoo Finance
2 Reasons to Avoid TROW and 1 Stock to Buy Instead - Yahoo Finance
REGT.Rowe Price Assoc BAWAG Group AGForm 8.3Bawag Group AG - TradingView
Rising Equity Markets and Diminished Outflows Should Continue To Lift T. Rowe Price's AUM - Morningstar
T. Rowe Price Reports 7.4% Stake in Block, Inc. Common Stock - theglobeandmail.com
Can T. Rowe Price Turn AI Adoption Into a Competitive Advantage? - Zacks Investment Research
Looking beyond tight credit spreads in high yield bonds - FT Adviser
T. Rowe Price CEO Rob Sharps Predicts 'Couple of Years' to Reverse Outflows - marketscreener.com
Winners And Losers Of Q2: T. Rowe Price (NASDAQ:TROW) Vs The Rest Of The Custody Bank Stocks - Yahoo Finance
Understanding the evolving opportunity for financial advice - T. Rowe Price
Vanguard taps T. Rowe Price to run portions of key active equity funds - thestreet.com
T. Rowe Price Associates Discloses 7.4% Stake in Block Inc via Schedule 13G/A Filing - Kalkine
Stoneridge Investment Partners LLC Purchases New Position in T. Rowe Price Group, Inc. $TROW - MarketBeat
Handelsbanken Fonder AB Has $3.10 Million Holdings in T. Rowe Price Group, Inc. $TROW - MarketBeat
T. Rowe Price (TROW) Q2 2026 Earnings Call Transcript - AOL.com
T. Rowe Price Group (NASDAQ:TROW) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
D.A. Davidson & CO. Has $6.46 Million Stake in T. Rowe Price Group, Inc. $TROW - MarketBeat
T. Rowe Price (TROW) Reworks Leadership To Speed AI Push And Back Crypto - Yahoo Finance
TROW|T Rowe Price Group Inc|Price:110.560|Chg%:-0.740 - TradingKey
T. Rowe Price Associates (THG) discloses 5.2% Hanover Insurance ownership stake - Stock Titan
T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan
T. Rowe Price Investment Management (PRAA) discloses 7.9% PRA Group ownership - Stock Titan
T. Rowe Price (VICR) discloses 7.0% beneficial stake in Vicor common stock - Stock Titan
T. Rowe Price Associates (MDWD) discloses 5.0% ownership in Mediwound common stock - Stock Titan
T. Rowe Price Investment Management (PCTY) discloses 5.8% Paylocity ownership in 13G/A - Stock Titan
T. Rowe Price (SVV) discloses 7.39M-share position in Savers Value Village - Stock Titan
T. Rowe Price Investment Management (AIZ) reports 4.9% Assurant stake in 13G/A - Stock Titan
T. Rowe Price Investment Management (MTSI) discloses 2.85M MACOM shares in 13G/A - Stock Titan
T. Rowe Price (UNIT) discloses 5.0% Uniti Group ownership in Schedule 13G/A - Stock Titan
T. Rowe Price Investment Management (GHM) discloses 5.2% Graham Corp ownership - stocktitan.net
T. Rowe Price Investment Management (PLNT) discloses 8.33M-share Planet Fitness stake - Stock Titan
T. Rowe Price Investment Management (GLNG) discloses 6.2% Golar LNG common stock holding - Stock Titan
T. Rowe Price Investment Management (TFX) discloses 7.2% ownership in Teleflex - stocktitan.net
T. Rowe Price Investment Management (MIAX) discloses 5.3% holding in Miami International - Stock Titan
T. Rowe Price Investment Management (STTK) reports 15.3% stake in Shattuck Labs - Stock Titan
T. Rowe Price Investment Management (MPTI) discloses 5.9% holding in M-TRON Industries - stocktitan.net
T. Rowe Price updates 6.5% Safehold Inc. (SAFE) ownership in Schedule 13G/A - Stock Titan
T. Rowe Price Investment Management (BELFA) discloses 4.4% Bel Fuse Inc-CL B holding - Stock Titan
T. Rowe Price Investment Management (NI) discloses 6.2% beneficial stake in NiSource - stocktitan.net
T. Rowe Price Investment Management (DCBG) discloses 7.2% Dime Community stake - Stock Titan
T. Rowe Price Investment Management (PTC) discloses 13.1M-share position in PTC Inc. - Stock Titan
T. Rowe Price Investment Management (EQBK) discloses 11.4% Equity Bancshares ownership - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
T. Rowe Price (STVN) cuts Stevanato stake to 3,921 shares, 0.0% - Stock Titan
T. Rowe Price Associates (HXL) discloses 5.86M-share position in Hexcel - Stock Titan
T. Rowe Price (WOLF) discloses 6.1M Wolfspeed shares held for clients - Stock Titan
T. Rowe Price (MQ) discloses 11.6% Marqeta stake; Mid-Cap Value Fund holds 5.1% - Stock Titan
Skyward Specialty (SKWD): T. Rowe Price Associates reports 6% ownership stake - Stock Titan
T. Rowe Price Associates (NTRA) discloses 9.0M-share Natera stake in updated 13G - Stock Titan
T. Rowe Price Associates (SMA) reports 5.27M-share, 9.5% stake in SmartStop - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Finanzdaten der T Rowe Price Group Inc-Aktie (TROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
T Rowe Price Group Inc-Aktie (TROW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MacLellan Robert F. | Director |
Feb 26 '26 |
Option Exercise |
74.14 |
4,417 |
327,480 |
52,759 |
| Husain Arif | VP |
Dec 10 '25 |
Sale |
101.96 |
4,260 |
434,336 |
47,102 |
1.99%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):